Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Ziye LiJianmin Luo

Abstract

The long noncoding RNA (lnc) maternally expressed 3 (MEG3) is downregulated in many types of cancers. However, the relationship between lncRNA MEG3, microRNA-21 (miR-21) and chronic myeloid leukemia (CML) blast crisis is unknown. This study examined bone marrow samples from 40 CML patients and 10 healthy donors. Proliferation and apoptosis assays, real-time polymerase chain reaction (PCR), bisulfite sequencing PCR, Western blotting, luciferase assay, RNA pull-down, RNA immunoprecipitation (RIP), co-immunoprecipitation (CoIP) and Chromatin immunoprecipitation (ChIP) were performed. We found that MEG3 and PTEN expression were down-regulated, whereas, MDM2, DNMT1 and miR-21 were up-regulated in the accelerated and blast phases of CML. Treated with 5-azacytidine decreased the level of MDM2, DNMT1 and miR21, but increased the level of MEG3 and PTEN. Overexpression of MEG3 and silencing the expression of miR-21 inhibited proliferation and induced apoptosis. MEG3 overexpression and silencing the expression of miR21 influence the levels of MMP-2, MMP-9, bcl-2 and Bax. MEG3 was able to interact with MDM2 and EZH2. MDM2 could interact with DNMT1 and PTEN. MYC and AKT can interact with EZH2. ChIP-seq showed that the promoter of KLF4 and S...Continue Reading

References

Aug 10, 2000·British Journal of Haematology·C G Geary
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Jun 3, 2005·Annals of Hematology·Rüdiger HehlmannAndreas Hochhaus
Sep 29, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jian-Hua LuoGeorge K Michalopoulos
Feb 26, 2009·Cell·Chris P PontingWolf Reik
Jan 5, 2011·Cancer Research·Miao-Chih TsaiHoward Y Chang
Oct 31, 2012·Frontiers in Genetics·Keiko Tano, Nobuyoshi Akimitsu
Jan 29, 2013·Cell·Carla A KlattenhoffLaurie A Boyer
Mar 13, 2014·International Journal of Hematology·Juan R Alvarez-DominguezHarvey F Lodish
Oct 23, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Li ZhangLi Wang
Jan 7, 2017·Journal of Experimental & Clinical Cancer Research : CR·Jun ZhangTingting Yao
Feb 14, 2017·Biomolecules & Therapeutics·Xiangyu ZhouZhiqiang Liu

❮ Previous
Next ❯

Citations

Apr 10, 2020·Biomarkers in Medicine·Ancuta JurjIoana Berindan-Neagoe
Feb 23, 2019·Pathology Oncology Research : POR·Arwa Al-RugeebahNarasimha Reddy Parine
Aug 16, 2019·World Journal of Gastroenterology : WJG·Wei WangQing-Chang Li
Sep 25, 2020·Asia-Pacific Journal of Clinical Oncology·Rana Muhammad UsmanFaiz Anwer
Oct 17, 2018·International Journal of Molecular Sciences·Mirco Di MarcoRosa Visone
Dec 30, 2020·International Journal of Laboratory Hematology·Mei JiangAiping Le
Feb 11, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·L GaoJ Ding

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.